2024-10-07 - Analysis Report
## Merck & Co Inc (MRK) Stock Analysis

**1. Performance Comparison**

Merck & Co Inc (MRK) is a global healthcare company that researches, develops, manufactures, and markets a wide range of prescription medicines, vaccines, and animal health products.

**MRK's cumulative return is 70.55%, while the S&P 500 (VOO) has a cumulative return of 133.14%. This means MRK has underperformed the benchmark by 62.59%.** This underperformance puts MRK at the 22.13 percentile of its historical performance range against the S&P 500. 

**2. Recent Price Action**

* **Closing price:** $109.77
* **5-day moving average:** $112.07
* **20-day moving average:** $114.91
* **60-day moving average:** $117.24

MRK's current price is below its 5, 20, and 60-day moving averages, indicating a potential downtrend in the short to medium term.

**3. Technical Indicators**

* **RSI:** 18.86 - This indicates the stock is oversold, potentially indicating a bounce back.
* **PPO:** -0.51 - This suggests a bearish momentum, supporting the downtrend observation.
* **Delta_Previous_Relative_Divergence:** -23.39 - This negative value implies a short-term downward trend.
* **Expected_Return:** 0.0% - Based on current data, over the next 5 years, MRK is not expected to outperform the S&P 500 significantly.

**4. Recent Earnings and Outlook**

| Date | EPS | Revenue |
|---|---|---|
| 2024-08-05 | 2.15 | 16.11 B$ |
| 2024-05-03 | 1.88 | 15.78 B$ |
| 2023-11-03 | 1.87 | 15.96 B$ |
| 2023-08-07 | -2.35 | 15.04 B$ |
| 2024-08-05 | -2.35 | 15.04 B$ |

MRK's most recent earnings report on 2024-08-05 showed an EPS of $2.15, beating the consensus estimate. However, the company's revenue of $16.11 billion came in slightly below expectations. Overall, recent earnings have shown a mixed picture with some improvements but also concerns about the company's ability to meet growth expectations.

**5. News and Recent Issues**

- Recent market outlook: The stock has been under pressure due to concerns about the company's growth prospects and its dependence on key products, such as Keytruda.
- Analyst Opinions: Analyst opinions are mixed with some suggesting a hold or sell rating while others remain optimistic about the long-term potential.
- Performance Highlights: MRK's performance has been impacted by various factors including increased competition in the pharmaceutical industry, regulatory challenges, and a difficult macroeconomic environment. 

**6. Overall Analysis**

MRK's stock has been underperforming the S&P 500 recently. While its latest earnings report showed an EPS beat, concerns remain about its growth prospects. The stock is currently oversold based on RSI, but PPO and the negative divergence indicate a bearish momentum in the short term.  Investors need to carefully consider the risks and opportunities associated with MRK's future performance before making investment decisions.

**7. Conclusion**

MRK's stock is currently underperforming the market and facing challenges with its growth trajectory. Despite recent earnings beating expectations, the overall outlook remains uncertain.  While the stock is oversold, technical indicators suggest a short-term downtrend. Investors should monitor the company's performance closely and consider their risk tolerance before making any investment decisions. 
